ArticleAdvances in rheumatology (London, England)2025
The vital role of CD19
Article in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunophenotyping of Human B Lymphocytes from Peripheral Blood Mononuclear Cells.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Review
- Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionRegulatory B cells (Bregs) play a pivotal role in the immune modulation of rheumatoid arthritis (RA). The levels of CD19+CD24hiCD38hi Bregs in peripheral blood and their association with clinical indicators in RA patients have not been extensively studied. The aim of this study was to investigate the alterations in peripheral blood CD19+CD24hiCD38hi Breg levels in RA patients and their association with clinical indicators. Additionally, we explored the variations in Breg levels before and after treatment.
methodsOverall, 90 patients with newly diagnosed RA and 32 healthy controls were prospectively enrolled. Symptoms and laboratory findings were collected. Flow cytometry and three-color fluorescence antibody labeling were employed to detect CD19+CD24hiCD38hi Breg levels in peripheral blood mononuclear cells (PBMCs). The proportion of CD19+CD24hiCD38hi Bregs among mature B lymphocytes was analyzed, and correlations with clinical indicators were examined. A follow-up study of 26 RA patients was conducted to compare changes in Breg levels before and after six months of treatment.
resultsThe levels of CD19+CD24hiCD38hi Bregs in RA patients were 89.63% of those in healthy controls. No significant differences in Breg levels were observed among patients with different disease activities. There was a positive correlation between CD19+CD24hiCD38hi Breg levels and morning stiffness duration (r = 0.227, p = 0.027), and negative correlations with age and anti-CCP antibody titers (r=-0.234, p = 0.022; r=-0.218, p = 0.036). No significant correlations were found between Breg proportions and other clinical indicators. The follow-up study showed a decrease in disease activity scores and a significant increase in CD19+CD24hiCD38hi Breg levels after six months of treatment.
conclusionsThese findings suggest a potential association between Breg levels and the pathogenesis and inflammatory activity of RA. CD19+CD24hiCD38hi Bregs may serve as potential biomarkers for evaluating disease activity and treatment efficacy. Further research is warranted to explore the underlying biological mechanisms and clinical significance of Bregs in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.